id
stringlengths
22
37
tokens
sequence
ner_tags
sequence
texts
stringlengths
0
39.2k
2275286-01-Abstract-p01
[ "Methods" ]
[ 0 ]
Methods
1360090-04-Discussion-p01
[ "In", "order", "to", "determine", "whether", "the", "characteristic", "clinicopathological", "features", "of", "tumors", "with", "BRAF", "mutation", "were", "due", "to", "their", "close", "association", "with", "MSI+", "and", "CIMP+,", "we", "stratified", "tumours", "according", "to", "these", "phenotypes.", "Despite", "having", "only", "9", "MSI-/BRAF", "mutant", "and", "5", "CIMP-/BRAF", "mutant", "tumors,", "the", "results", "showed", "that", "associations", "between", "BRAF", "mutation", "and", "the", "morphological", "properties", "of", "tumor-infiltrating", "infiltrating", "lymphocytes,", "poor", "histological", "grade", "and", "mucinous", "phenotype", "were", "retained", "(Tables", "3", "and", "4)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
In order to determine whether the characteristic clinicopathological features of tumors with BRAF mutation were due to their close association with MSI+ and CIMP+, we stratified tumours according to these phenotypes. Despite having only 9 MSI-/BRAF mutant and 5 CIMP-/BRAF mutant tumors, the results showed that associations between BRAF mutation and the morphological properties of tumor-infiltrating infiltrating lymphocytes, poor histological grade and mucinous phenotype were retained (Tables 3 and 4).
1334229-03-Methods-p02
[ "All", "464", "samples", "without", "a", "truncating", "APC", "mutation", "(n", "=", "411)", "and", "all", "samples", "with", "absent", "hMLH1", "expression", "(n", "=", "58)", "were", "analysed", "for", "mutations", "in", "the", "phosphorylation", "sites", "at", "codons", "33,", "37,", "41", "and", "45", "in", "exon", "3", "of", "the", "CTNNB1", "gene.", "This", "selection", "was", "made,", "since", "most", "mutations", "are", "expected", "in", "these", "samples.", "Tumours", "lacking", "truncating", "APC", "mutations", "may", "harbour", "CTNNB1", "mutations", "[7],", "and", "microsatellite", "instable", "tumours", "are", "also", "expected", "to", "more", "frequently", "have", "mutations", "in", "CTNNB1", "[26]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
All 464 samples without a truncating APC mutation (n = 411) and all samples with absent hMLH1 expression (n = 58) were analysed for mutations in the phosphorylation sites at codons 33, 37, 41 and 45 in exon 3 of the CTNNB1 gene. This selection was made, since most mutations are expected in these samples. Tumours lacking truncating APC mutations may harbour CTNNB1 mutations [7], and microsatellite instable tumours are also expected to more frequently have mutations in CTNNB1 [26].
1557864-05-Discussion-p01
[ "Next", "we", "studied", "the", "association", "between", "MMR", "inactivation", "and", "cisplatin", "resistance", "in", "these", "cell", "lines.", "MMR", "inactivation", "seen", "in", "SKOV3", "and", "2774", "might", "result", "in", "the", "relative", "resistance", "to", "cisplatin", "compared", "to", "the", "other", "cell", "lines.", "On", "the", "other", "hand,", "A2780", "which", "has", "clearly", "an", "inactive", "MMR,", "was", "most", "sensitive", "to", "cisplatin.", "Overall,", "there", "seems", "to", "be", "no", "association", "between", "the", "response", "to", "cisplatin", "and", "MMR", "status", "in", "these", "eight", "cell", "lines.", "This", "is", "similar", "to", "a", "study", "in", "the", "60", "NCI", "cell", "lines", "MLH1", " ", "allele", "was", "methylated", "in", "A2780", "[12]", "which", "is", "comparable", "with", "the", "methylation", "status", "we", "saw", "in", "A2780,", "moreover", "one", "of", "our", "A2780", "sublines", "showed", "complete", "methylation.", "On", "the", "other", "hand,", "another", "study", "did", "not", "detect", "MSI", "in", "A2780", "[11].", "Interestingly,", "Aquilina", "and", "colleagues", "suggested", "there", "is", "a", "subpopulation", "of", "A2780", "cells,", "estimated", "to", "be", "around", "one", "per", "106", "cells", "[46],", "which", "are", "MLH1", "deficient", "and", "heterozygous", "for", "the", "p53phe172", "mutation", "[46,47].", "Since", "these", "cells", "have", "a", "growth", "advantage,", "prolonged", "culturing", "of", "the", "A2780", "cell", "line", "can", "result", "in", "selection", "of", "this", "subpopulation.", "Thus", "over", "time,", "separately", "cultured", "A2780", "can", "have", "varying", "percentages", "of", "cells", "belonging", "to", "this", "subpopulation", "which", "may", "explain", "the", "discrepancies", "in", "MMR", "status", "seen", "in", "the", "A2780", "cell", "lines", "analyzed", "by", "us." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 10, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Next we studied the association between MMR inactivation and cisplatin resistance in these cell lines. MMR inactivation seen in SKOV3 and 2774 might result in the relative resistance to cisplatin compared to the other cell lines. On the other hand, A2780 which has clearly an inactive MMR, was most sensitive to cisplatin. Overall, there seems to be no association between the response to cisplatin and MMR status in these eight cell lines. This is similar to a study in the 60 NCI cell lines MLH1 allele was methylated in A2780 [12] which is comparable with the methylation status we saw in A2780, moreover one of our A2780 sublines showed complete methylation. On the other hand, another study did not detect MSI in A2780 [11]. Interestingly, Aquilina and colleagues suggested there is a subpopulation of A2780 cells, estimated to be around one per 106 cells [46], which are MLH1 deficient and heterozygous for the p53phe172 mutation [46,47]. Since these cells have a growth advantage, prolonged culturing of the A2780 cell line can result in selection of this subpopulation. Thus over time, separately cultured A2780 can have varying percentages of cells belonging to this subpopulation which may explain the discrepancies in MMR status seen in the A2780 cell lines analyzed by us.
1619718-05-Discussion-p01
[ "Adenomas" ]
[ 0 ]
Adenomas
2386495-05-Discussion-p04
[ "The", "61", "different", "APC", "mutations", "listed", "in", "Additional", "file", "2", "were", "identified", "among", "81", "of", "the", "96", "families", "of", "the", "Swedish", "Polyposis", "Registry", "that", "were", "screened", "for", "APC", "mutations.", "Fifteen", "of", "the", "cases", "shown", "to", "be", "APC-mutation", "negative", "where", "all", "subjected", "to", "mutational", "screening", "of", "the", "MUTYH", "gene", "and", "six", "of", "them", "were", "shown", "to", "carry", "biallelic", "MUTYH", "mutations", "(reported", "in", "Kanter", "Smoler", "et", "al[31]).", "The", "overall", "mutation-detection", "rate", "in", "APC", "and", "MUTYH", "among", "the", "families", "families", "Family", "1", " ", "is", "the", "largest", "kindred", "in", "the", "Swedish", "Polyposis", "Registry;", "this", "family", "includes", "150", "individuals", "of", "whom", "57", "are", "affected", "by", "the", "disease", "(Figure", "6", "shows", "part", "of", "the", "pedigree).", "However,", "no", "pathogenic", "mutation", "had", "been", "detected", "after", "screening", "the", "whole", "coding", "region", "of", "the", "APC", "gene", "but", "as", "the", "family", "did", "show", "positive", "linkage", "to", "the", "APC", "locus", "we", "decided", "to", "perform", "expression", "analyses", "and", "evidence", "of", "lowered", "APC", "expression", "was", "obtained", "by", "quantitative", "real-time", "PCR", "(Figure", "5A).", "The", "result", "was", "supported", "by", "the", "indication", "of", "a", "lower", "expression", "from", "the", "T-allele", "from", "analysis", "of", "the", "APC", "c.5465A", ">", "T", "polymorphism", "in", "the", "cDNA", "sequencing", "diagram", "of", "two", "affected", "family", "members", "(Figure", "5B).", "The", "search", "for", "mutations", "in", "the", "DNA", "sequence", "of", "the", "APC", "promoters", "has", "been", "initiated,", "but", "no", "pathogenic", "change", "has", "been", "detected", "to", "this", "date.", "The", "possibility", "of", "the", "pathogenic", "change", "being", "epigenetic", "will", "have", "to", "be", "investigated", "further.", "Hypermethylation", "of", "CpG", "sites", "in", "the", "promoter", "of", "APC", "has", "been", "reported", "as", "a", "means", "of", "gene", "silencing", "in", "colorectal", "tumors", "[46-49].", "To", "the", "best", "of", "the", "authors'", "knowledge", "no", "germ-line", "inactivation", "of", "APC", "caused", "by", "promoter", "hypermethylation", "has", "been", "reported.", "However,", "cases", "of", "pathogenic", "germline", "epimutations", "have", "been", "identified", "in", "the", "MLH1", "gene,", "which", "causes", "hereditary", "non-polyposis", "CRC", "[50,51]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 9, 9, 10, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The 61 different APC mutations listed in Additional file 2 were identified among 81 of the 96 families of the Swedish Polyposis Registry that were screened for APC mutations. Fifteen of the cases shown to be APC-mutation negative where all subjected to mutational screening of the MUTYH gene and six of them were shown to carry biallelic MUTYH mutations (reported in Kanter Smoler et al[31]). The overall mutation-detection rate in APC and MUTYH among the families families Family 1 is the largest kindred in the Swedish Polyposis Registry; this family includes 150 individuals of whom 57 are affected by the disease (Figure 6 shows part of the pedigree). However, no pathogenic mutation had been detected after screening the whole coding region of the APC gene but as the family did show positive linkage to the APC locus we decided to perform expression analyses and evidence of lowered APC expression was obtained by quantitative real-time PCR (Figure 5A). The result was supported by the indication of a lower expression from the T-allele from analysis of the APC c.5465A > T polymorphism in the cDNA sequencing diagram of two affected family members (Figure 5B). The search for mutations in the DNA sequence of the APC promoters has been initiated, but no pathogenic change has been detected to this date. The possibility of the pathogenic change being epigenetic will have to be investigated further. Hypermethylation of CpG sites in the promoter of APC has been reported as a means of gene silencing in colorectal tumors [46-49]. To the best of the authors' knowledge no germ-line inactivation of APC caused by promoter hypermethylation has been reported. However, cases of pathogenic germline epimutations have been identified in the MLH1 gene, which causes hereditary non-polyposis CRC [50,51].
3034663-03-Methods-p01
[ "Three", "characterized", "LS", "families", "that", "fulfilled", "the", "Amsterdam", "II", "Criteria", "and", "that", "consisted", "of", "members", "with", "the", "p.Lys618Ala", "variant", "were", "included", "to", "assess", "co-occurrence", "and", "co-segregation.", "Two", "families", "attended", "the", "Genetic", "Counselling", "in", "Cancer", "Units", "of", "the", "Elche", "and", "La", "Fe", "Hospitals", "and", "one", "family", "was", "a", "member", "of", "the", "EPICOLON", "cohort", "[7]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Three characterized LS families that fulfilled the Amsterdam II Criteria and that consisted of members with the p.Lys618Ala variant were included to assess co-occurrence and co-segregation. Two families attended the Genetic Counselling in Cancer Units of the Elche and La Fe Hospitals and one family was a member of the EPICOLON cohort [7].
1334229-01-Abstract-p01
[ "Methods" ]
[ 0 ]
Methods
1601966-06-Methods-p02
[ "Preprocessing", "of", "expression", "data" ]
[ 0, 0, 0, 0 ]
Preprocessing of expression data
2275286-01-Abstract-p01
[ "Methods" ]
[ 0 ]
Methods
2386495-03-Methods-p01
[ "DNA,", "RNA", "and", "cDNA", "preparation" ]
[ 0, 0, 0, 0, 0 ]
DNA, RNA and cDNA preparation
1334229-01-Abstract-p01
[ "In", "a", "group", "of", "656", "unselected", "sporadic", "colorectal", "cancer", "patients,", "aberrations", "in", "the", "APC,", "K-ras,", "CTNNB1", "genes,", "and", "expression", "of", "hMLH1", "were", "investigated.", "Additionally,", "tumours", "were", "divided", "in", "groups", "based", "on", "molecular", "features", "and", "compared", "with", "respect", "to", "patient's", "age", "at", "diagnosis,", "sex,", "family", "history", "of", "colorectal", "cancer,", "tumour", "sub-localisation,", "Dukes'", "stage", "and", "differentiation." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
In a group of 656 unselected sporadic colorectal cancer patients, aberrations in the APC, K-ras, CTNNB1 genes, and expression of hMLH1 were investigated. Additionally, tumours were divided in groups based on molecular features and compared with respect to patient's age at diagnosis, sex, family history of colorectal cancer, tumour sub-localisation, Dukes' stage and differentiation.
1334229-02-Background-p01
[ "Activation", "of", "the", "Wnt", "pathway", "plays", "a", "central", "role", "in", "the", "aetiology", "of", "most", "colorectal", "cancers", "and", "is", "often", "the", "result", "of", "mutations", "in", "the", "N-terminal", "domain", "of", "the", "APC", "gene,", "that", "lead", "to", "partial", "or", "complete", "loss", "of", "this", "region", "and", "thereby", "to", "loss", "of", "the", "β-catenin", "regulating", "function", "[5,6].", "Conversely,", "in", "tumours", "lacking", "these", "APC", "mutations", "[7],", "activating", "missense", "mutations", "at", "one", "of", "the", "phosphorylation", "sites", "at", "codons", "31,", "33,", "37", "and", "45", "of", "exon", "3", "of", "the", "CTNNB1", "gene", "(encoding", "the", "β-catenin", "protein)", "can", "render", "it", "stable", "as", "it", "can", "no", "longer", "be", "tagged", "for", "cellular", "degradation.", "Activation", "of", "the", "Ras", "pathway", "in", "cancer", "is", "marked", "by", "the", "loss", "of", "the", "intrinsic", "GTPase", "activity", "of", "the", "Ras", "protein,", "which", "can", "be", "ascribed", "to", "missense", "mutations", "in", "codons", "12", "and", "13", "of", "exon", "1,", "which", "are", "responsible", "for", "90%", "activating", "mutations", "in", "the", "of", "the", "K-ras", "gene", "[8]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Activation of the Wnt pathway plays a central role in the aetiology of most colorectal cancers and is often the result of mutations in the N-terminal domain of the APC gene, that lead to partial or complete loss of this region and thereby to loss of the β-catenin regulating function [5,6]. Conversely, in tumours lacking these APC mutations [7], activating missense mutations at one of the phosphorylation sites at codons 31, 33, 37 and 45 of exon 3 of the CTNNB1 gene (encoding the β-catenin protein) can render it stable as it can no longer be tagged for cellular degradation. Activation of the Ras pathway in cancer is marked by the loss of the intrinsic GTPase activity of the Ras protein, which can be ascribed to missense mutations in codons 12 and 13 of exon 1, which are responsible for 90% activating mutations in the of the K-ras gene [8].
1619718-05-Discussion-p01
[ "The", "adenomas", "in", "this", "study", "were", "grouped", "as", "TAs", "<", " ", "10", "mm,", "TAs", ">", " ", "10", "mm", "and", "TVAs/VAs.", "Overall,", "KRAS", "mutation", "occurred", "in", "26.5%", "of", "adenomas", "while", "BRAF", "mutation", "was", "detected", "in", "only", "4.8%.", "Three", "of", "the", "four", "BRAF", "mutations", "occurred", "in", "adenomas", "that", "also", "had", "KRAS", "mutation.", "It", "is", "well", "established", "that", "BRAF", "and", "KRAS", "mutation", "rarely", "occur", "in", "the", "same", "colorectal", "neoplasm.12,16,30", "Furthermore,", "BRAF", "mutations", "are", "much", "more", "typical", "of", "serrated", "polyps", "than", "adenomas.14,31", "The", "assay", "for", "BRAF", "mutation", "used", "in", "this", "study", "was", "highly", "sensitive", "and", "it", "is", "possible", "that", "the", "mutation", "was", "being", "identified", "in", "normal", "mucosa", "included", "with", "the", "polyp.", "KRAS", "mutation", "may", "occur", "within", "apparently", "normal", "colorectal", "mucosa", "and", "the", "same", "could", "apply", "to", "BRAF.32", "Therefore,", "the", "finding", "of", "BRAF", "mutation", "in", "a", "small", "subset", "of", "adenomas", "could", "be", "spurious", "and", "the", "true", "incidence", "of", "BRAF", "mutation", "in", "colorectal", "adenomas", " ", "could", "be", "lower", "than", "4.8%.", "BRAF", "mutation", "frequencies", "of", "0%14", "and", "3%31", "have", "been", "reported", "in", "other", "series", "of", "colorectal", "adenomas." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The adenomas in this study were grouped as TAs <   10 mm, TAs >   10 mm and TVAs/VAs. Overall, KRAS mutation occurred in 26.5% of adenomas while BRAF mutation was detected in only 4.8%. Three of the four BRAF mutations occurred in adenomas that also had KRAS mutation. It is well established that BRAF and KRAS mutation rarely occur in the same colorectal neoplasm.12,16,30 Furthermore, BRAF mutations are much more typical of serrated polyps than adenomas.14,31 The assay for BRAF mutation used in this study was highly sensitive and it is possible that the mutation was being identified in normal mucosa included with the polyp. KRAS mutation may occur within apparently normal colorectal mucosa and the same could apply to BRAF.32 Therefore, the finding of BRAF mutation in a small subset of adenomas could be spurious and the true incidence of BRAF mutation in colorectal adenomas could be lower than 4.8%. BRAF mutation frequencies of 0%14 and 3%31 have been reported in other series of colorectal adenomas.
2275286-01-Abstract-p01
[ "Hereditary", "nonpolyposis", "colorectal", "cancer", "(HNPCC)", "is", "an", "autosomal", "dominant", "syndrome.", "The", "National", "Cancer", "Institute", "(NCI)", "has", "recommended", "the", "Revised", "Bethesda", "guidelines", "for", "screening", "HNPCC.", "There", "has", "been", "a", "great", "deal", "of", "research", "on", "the", "value", "of", "these", "tests", "in", "other", "countries.", "However,", "literature", "about", "the", "Chinese", "population", "is", "scarce.", "Our", "objective", "is", "to", "detect", "and", "study", "microsatellite", "instability", "(MSI)", "and", "mismatch", "repair", "(MMR)", "gene", "germline", "mutation", "carriers", "among", "a", "Chinese", "population", "with", "colorectal", "cancer." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant syndrome. The National Cancer Institute (NCI) has recommended the Revised Bethesda guidelines for screening HNPCC. There has been a great deal of research on the value of these tests in other countries. However, literature about the Chinese population is scarce. Our objective is to detect and study microsatellite instability (MSI) and mismatch repair (MMR) gene germline mutation carriers among a Chinese population with colorectal cancer.
1557864-02-Background-p01
[ "Inactivation", "of", "MMR", "leads", "to", "the", "occurrence", "of", "unrepaired", "deletions", "in", "mono-", "and", "dinucleotide", "repeats", "resulting", "in", "variable", "lengths", "of", "these", "repeats.", "This", "is", "called", "microsatellite", "instability", "(MSI)", "and", "MSI", "is", "therefore", "used", "as", "a", "marker", "for", "MMR", "deficiency.", "MSI", "can", "be", "caused", "by", "genetic", "or", "epigenetic", "inactivation", "of", "several", "genes", "involved", "in", "MMR.", "Mouse", "knockout", "models", "have", "demonstrated", "that", "MSH2-/-,", "MSH3-/-,", "MLH1-/-", "and", "PMS2-/-", "leads", "to", "a", "high", "frequency", "of", "MSI", "while", "MSH6-/-", "and", "PMS1-/-", "cause", "a", "low", "frequency", "(reviewed", "by", "Wei", "et", "al.", "[10]).", "However,", "in", "hereditary", "nonpolyposis", "colon", "cancer", "(HNPCC)", "families", "(which", "are", "known", "to", "have", "a", "high", "frequency", "of", "MSI)", "germline", "mutations", "in", "MSH2", "and", "MLH1", "are", "responsible", "for", "the", "MSI,", "while", "MSH6", "and", "PMS2", "hereditary", "nonpolyposis", "colon", "cancer", "MMR", ".", "Other", "known", "and", "still", "unknown", "proteins", "involved", "in", "the", "last", "two", "steps", "of", "MMR,", "the", "excision", "of", "the", "damaged", "strand", "and", "the", "resynthesis,", "are", "recruited", "subsequently.", "Proteins", "known", "to", "be", "involved", "are", "exonuclease", "ExoI,", "proliferating", "cell", "nuclear", "antigen", "(PCNA),", "DNA", "polymerase", "δ", "and", "perhaps", "ε", "and", "in", "addition", "based", "on", "its", "association", "with", "DNA", "polymerase", "δ", "and", "PCNA,", "DNA", "ligase", "I", "[8,9]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 1, 2, 2, 2, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Inactivation of MMR leads to the occurrence of unrepaired deletions in mono- and dinucleotide repeats resulting in variable lengths of these repeats. This is called microsatellite instability (MSI) and MSI is therefore used as a marker for MMR deficiency. MSI can be caused by genetic or epigenetic inactivation of several genes involved in MMR. Mouse knockout models have demonstrated that MSH2-/-, MSH3-/-, MLH1-/- and PMS2-/- leads to a high frequency of MSI while MSH6-/- and PMS1-/- cause a low frequency (reviewed by Wei et al. [10]). However, in hereditary nonpolyposis colon cancer (HNPCC) families (which are known to have a high frequency of MSI) germline mutations in MSH2 and MLH1 are responsible for the MSI, while MSH6 and PMS2 hereditary nonpolyposis colon cancer MMR . Other known and still unknown proteins involved in the last two steps of MMR, the excision of the damaged strand and the resynthesis, are recruited subsequently. Proteins known to be involved are exonuclease ExoI, proliferating cell nuclear antigen (PCNA), DNA polymerase δ and perhaps ε and in addition based on its association with DNA polymerase δ and PCNA, DNA ligase I [8,9].
1334229-03-Methods-p01
[ "The", "PALGA", "reports", "were", "used", "to", "identify", "and", "locate", "tumour", "tissue", "from", "eligible", "colorectal", "cancer", "patients", "in", "Dutch", "pathology", "laboratories.", "Colon", "and", "rectal", "cancer", "were", "classified", "according", "to", "site", "as", "follows,", "colon:", "cecum", "through", "sigmoid", "colon", "(ICD-O", "codes", "153.0,", "153.1,", "153.2,", "153.3,", "153.4,", "153.5,", "153.6,", "153.7),", "rectosigmoid", "(ICD-O", "code", "154.0),", "and", "rectum", "(ICD-O", "code", "154.1)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The PALGA reports were used to identify and locate tumour tissue from eligible colorectal cancer patients in Dutch pathology laboratories. Colon and rectal cancer were classified according to site as follows, colon: cecum through sigmoid colon (ICD-O codes 153.0, 153.1, 153.2, 153.3, 153.4, 153.5, 153.6, 153.7), rectosigmoid (ICD-O code 154.0), and rectum (ICD-O code 154.1).
1619718-03-Materials-and-methods-p01
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
1557864-03-Methods-p02
[ "Microsatellite", "analysis", "was", "standard", "performed", "in", "our", "laboratory", "as", "described", "by", "Westenend", "et", "al", "[40]", "using", "the", "two", "mononucleotide", "markers,", "BAT25", "and", "BAT26.", "In", "addition,", "the", "75", " ", "ovarian", "carcinomas", "were", "also", "analysed", "with", "the", "mononucleotide", "marker", "BAT40", "(n", "=", "42)", "or", "with", "the", "dinucleotide", "marker", "D2S123", "(n", "=", "40).", "So", "all", "ovarian", "carcinomas", "were", "analysed", "with", "three", "or", "four", "MSI", "markers.", "A", "PCR", "containing", "α-32PdATP,", "was", "performed", "on", "100", "ng", "DNA.", "PCR", "products", "were", "separated", "on", "a", "denaturing", "6%", "polyacrylamide", "gel.", "After", "electrophoresis,", "gels", "were", "dried", "on", "blotting", "paper", "on", "a", "vacuum", "gel", "dryer", "and", "exposed", "to", "x-ray", "film.", "The", "films", "were", "evaluated", "by", "visual", "inspection." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Microsatellite analysis was standard performed in our laboratory as described by Westenend et al [40] using the two mononucleotide markers, BAT25 and BAT26. In addition, the 75 ovarian carcinomas were also analysed with the mononucleotide marker BAT40 (n = 42) or with the dinucleotide marker D2S123 (n = 40). So all ovarian carcinomas were analysed with three or four MSI markers. A PCR containing α-32PdATP, was performed on 100 ng DNA. PCR products were separated on a denaturing 6% polyacrylamide gel. After electrophoresis, gels were dried on blotting paper on a vacuum gel dryer and exposed to x-ray film. The films were evaluated by visual inspection.
1619718-03-Materials-and-methods-p02
[ "BRAF", "mutation", "analysis", "at", "codon", "600", "(V600E;", "formerly", "V599E)", "was", "performed", "by", "a", "real-time", "PCR-based", "allelic", "discrimination", "method", "as", "previously", "described.29", "Briefly,", "real-time", "PCR", "was", "performed", "using", "allele-specific", "primers", "designed", "to", "amplify", "selectively", "the", "wild-type", "(T1796)", "and", "mutant", "(A1796)", "BRAF", "alleles.", "The", "primer", "sequences", "were", "as", "follows:", "V,", "5′-GTGATTTTGGTCTAGCTACtGT;", "E,", "5′-CGCGGCCGGCCGCGGCGGTGATTTTGGTCTAGCTACcGA;", "AS,", "5′-TAGCCTCAATTCTTACCATCCAC.", "PCR", "amplification", "and", "melting", "curve", "analysis", "were", "performed", "on", "a", "Rotor-gene", "3000", "(Corbett", "Research,", "NSW,", "Australia).", "Genomic", "DNA", "was", "amplified", "in", "a", "15-µl", "volume", "containing", "1", "×", "Platinum", "SYBR", "Green", "qPCR", "SuperMix-UDG", "(Invitrogen,", "Carlsbad,", "CA,", "USA),", "forward", "primer", "V", "(300", "nm),", "forward", "primer", "E", "(900", "nm)", "and", "reverse", "primer", "AS", "(300", "nm).", "The", "cycling", "conditions", "were", "as", "follows:", "50°C", "for", "2", "min,", "95°C", "for", "2", "min,", "40", "cycles", "of", "95°C", "for", "15", "s", "and", "60°C", "for", "60", "s.", "After", "amplification,", "samples", "were", "subjected", "to", "a", "temperature", "ramp", "from", "60°C", "to", "99°C,", "rising", "1°C", "each", "step.", "For", "wild-type", "samples,", "single", "peaks", "were", "observed", "at", "80°C", "while", "samples", "containing", "mutant", "alleles", "produced", "single", "peaks", "at", "85°C." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
BRAF mutation analysis at codon 600 (V600E; formerly V599E) was performed by a real-time PCR-based allelic discrimination method as previously described.29 Briefly, real-time PCR was performed using allele-specific primers designed to amplify selectively the wild-type (T1796) and mutant (A1796) BRAF alleles. The primer sequences were as follows: V, 5′-GTGATTTTGGTCTAGCTACtGT; E, 5′-CGCGGCCGGCCGCGGCGGTGATTTTGGTCTAGCTACcGA; AS, 5′-TAGCCTCAATTCTTACCATCCAC. PCR amplification and melting curve analysis were performed on a Rotor-gene 3000 (Corbett Research, NSW, Australia). Genomic DNA was amplified in a 15-µl volume containing 1 × Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen, Carlsbad, CA, USA), forward primer V (300 nm), forward primer E (900 nm) and reverse primer AS (300 nm). The cycling conditions were as follows: 50°C for 2 min, 95°C for 2 min, 40 cycles of 95°C for 15 s and 60°C for 60 s. After amplification, samples were subjected to a temperature ramp from 60°C to 99°C, rising 1°C each step. For wild-type samples, single peaks were observed at 80°C while samples containing mutant alleles produced single peaks at 85°C.
2386495-01-Abstract-p01
[ "Sixty-one", "different", "APC", "mutations", "in", "81", "of", "the", "96", "families", "were", "identified", "and", "27", "of", "those", "are", "novel.", "We", "have", "previously", "shown", "that", "6", "of", "the", "96", "patients", "carried", "biallelic", "MUTYH", "mutations.", "The", "9", "mutation-negative", "cases", "all", "display", "an", "attenuated", "or", "atypical", "phenotype.", "Probands", "with", "a", "genotype", "(codon", "1250–1464)", "predicting", "a", "severe", "phenotype", "had", "a", "median", "age", "at", "diagnosis", "of", "21.8", "(range,", "11–49)", "years", "compared", "with", "34.4", "(range,", "14–57)", "years", "among", "those", "with", "mutations", "outside", "this", "region", "(P", "<", "0.017).", "Dense", "polyposis", "familial", "adenomatous", "polyposis", " ", "(FAP)", "is", "caused", "by", "germline", "mutations", "in", "the", "APC", "gene.", "Finding", "the", "causative", "mutations", "has", "great", "implications", "for", "the", "families.", "Correlating", "the", "genotypes", "to", "the", "phenotypes", "could", "help", "to", "improve", "the", "diagnosis", "and", "follow-up", "of", "patients." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 19, 20, 1, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Sixty-one different APC mutations in 81 of the 96 families were identified and 27 of those are novel. We have previously shown that 6 of the 96 patients carried biallelic MUTYH mutations. The 9 mutation-negative cases all display an attenuated or atypical phenotype. Probands with a genotype (codon 1250–1464) predicting a severe phenotype had a median age at diagnosis of 21.8 (range, 11–49) years compared with 34.4 (range, 14–57) years among those with mutations outside this region (P < 0.017). Dense polyposis familial adenomatous polyposis (FAP) is caused by germline mutations in the APC gene. Finding the causative mutations has great implications for the families. Correlating the genotypes to the phenotypes could help to improve the diagnosis and follow-up of patients.
1557864-03-Methods-p02
[ "Quantitative", "RT-PCR", "analysis", "was", "used", "to", "measure", "the", "mRNA", "expression", "levels", "of", "MLH1,", "MSH2,", "MSH3,", "MSH6", "and", "PMS2", "in", "the", "eight", "ovarian", "cancer", "cancer", " ", "cell", "lines", "SW48", "with", "a", "methylated", "MLH1", "promoter", "and", "SW480", "with", "an", "unmethylated", "MLH1", "promoter,", "were", "used", "as", "positive", "and", "negative", "control", "respectively." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 2, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Quantitative RT-PCR analysis was used to measure the mRNA expression levels of MLH1, MSH2, MSH3, MSH6 and PMS2 in the eight ovarian cancer cancer cell lines SW48 with a methylated MLH1 promoter and SW480 with an unmethylated MLH1 promoter, were used as positive and negative control respectively.
1557864-05-Discussion-p03
[ "Another", "difference", "between", "the", "studies", "is", "the", "distribution", "of", "the", "various", "histological", "types", "of", "the", "ovarian", "carcinoma", "tissues", "analyzed", "(Table", "2).", "This", "difference", "in", "the", "distribution", "could", "be", "a", "cause", "for", "the", "wide", "range", "in", "the", "MSI", "frequency", "especially", "since", "it", "has", "been", "suggested", "that", "certain", "histological", "types", "have", "a", "higher", "frequency", "of", "MSI.", "To", "determine", "whether", "there", "is", "a", "relation", "between", "histology", "and", "MSI", "within", "these", "studies,", "we", "looked", "at", "the", "frequency", "of", "MSI", "per", "histological", "type", "for", "the", "628", "patients", "with", "known", "histology", "(Table", "2).", "The", "summary", "of", "these", "studies", "suggests", "that", "the", "frequency", "of", "MSI", "is", "higher", "in", "the", "mucinous", "and", "endometrioid", "adenocarcinoma", "compared", "to", "clear", "cell", "and", "serous", "adenocarcinoma", "(the", "overall", "frequencies", "of", "MSI", "were", "22%,", "16%,", "9%", "and", "8%,", "respectively)", "(Table", "2).", "We", "hypothesize", "that", "mucinous", "and", "endometrioid", "histology", "might", "be", "prone", "to", "a", "higher", "MSI", "frequency", "since", "sporadic", "endometrial", "carcinoma,", "which", "is", "closely", "related", "to", "endometrioid", "ovarian", "cancer,", "has", "a", "MSI", "frequency", "of", "20–30%", "[49-51]", "and", "MSI", "is", "almost", "universal", "present", "in", "the", "colorectal", "tumors", "of", "the", "hereditary", "nonpolyposis", "colon", "cancer", "(HNPCC)", "syndrome", "which", "all", "have", "a", "mucinous", "histological", "type.", "Therefore,", "the", "different", "histology's", "of", "the", "ovarian", "carcinomas", "included", "in", "the", "several", "studies", "seems", "to", "be", "a", "plausible", "cause", "for", "the", "wide", "range", "in", "MSI", "frequency", "reported", "in", "these", "studies." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Another difference between the studies is the distribution of the various histological types of the ovarian carcinoma tissues analyzed (Table 2). This difference in the distribution could be a cause for the wide range in the MSI frequency especially since it has been suggested that certain histological types have a higher frequency of MSI. To determine whether there is a relation between histology and MSI within these studies, we looked at the frequency of MSI per histological type for the 628 patients with known histology (Table 2). The summary of these studies suggests that the frequency of MSI is higher in the mucinous and endometrioid adenocarcinoma compared to clear cell and serous adenocarcinoma (the overall frequencies of MSI were 22%, 16%, 9% and 8%, respectively) (Table 2). We hypothesize that mucinous and endometrioid histology might be prone to a higher MSI frequency since sporadic endometrial carcinoma, which is closely related to endometrioid ovarian cancer, has a MSI frequency of 20–30% [49-51] and MSI is almost universal present in the colorectal tumors of the hereditary nonpolyposis colon cancer (HNPCC) syndrome which all have a mucinous histological type. Therefore, the different histology's of the ovarian carcinomas included in the several studies seems to be a plausible cause for the wide range in MSI frequency reported in these studies.
1334229-03-Methods-p01
[ "Tissue", "samples" ]
[ 0, 0 ]
Tissue samples
1619718-05-Discussion-p02
[ "Serrated", "polyps", "with", "dysplasia,", "i.e.", "MPs", "and", "SAs,", "together", "comprised", "only", "2%", "of", "the", "overall", "consecutive", "series", "of", "1250", "polyps.", "While", "mutation", "of", "KRAS", "SSA" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 1 ]
Serrated polyps with dysplasia, i.e. MPs and SAs, together comprised only 2% of the overall consecutive series of 1250 polyps. While mutation of KRAS SSA
3034663-04-Results-p02
[ "The", "MSI-positive", "patient", "from", "the", "familial", "CRC", "group", "showed", "loss", "of", "immunohistochemical", "expression", "of", "MLH1.", "This", "is", "the", "index", "subject", "(II-3)", "for", "the", "third", "family", "(Figure", "4)", "and", "no", "hypermethylation", "of", "MLH1", "gene", "promoter", "third", "family", "index", "subject", "patient", "familial", " ", "CRC", "group", " ", "(1/8)", "and", "one", "in", "the", "sporadic", " ", "CRC", "group", "(1/9)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 7, 8, 8, 8, 8, 8, 9, 10, 9, 10, 9, 17, 0, 0, 9, 0, 0, 0, 0, 0, 0, 17, 0, 0, 0, 0 ]
The MSI-positive patient from the familial CRC group showed loss of immunohistochemical expression of MLH1. This is the index subject (II-3) for the third family (Figure 4) and no hypermethylation of MLH1 gene promoter third family index subject patient familial CRC group (1/8) and one in the sporadic CRC group (1/9).
3034663-04-Results-p01
[ "Pedigree", "for", "Family", "#2", "(CRC:", "Colorectal", "cancer;", "EC", "p.Lys618Ala", "2.68%", "),", "nine", "were", "CRC", "patients", "from", "the", "sporadic", "group", "(9/373,", "2.41%)", "and", "seven", "were", "CRC", "patients", "from", "the", "familial", "group", "(7/250,", "2.8%).", "None", "of", "the", "individuals", "was", "homozygous", "for", "the", "minor", "allele." ]
[ 0, 0, 0, 0, 0, 0, 0, 1, 5, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Pedigree for Family #2 (CRC: Colorectal cancer; EC p.Lys618Ala 2.68% ), nine were CRC patients from the sporadic group (9/373, 2.41%) and seven were CRC patients from the familial group (7/250, 2.8%). None of the individuals was homozygous for the minor allele.
1619718-05-Discussion-p03
[ "Concept", "of", "‘fusion’", "pathways", "to", "crc" ]
[ 0, 0, 0, 0, 0, 0 ]
Concept of ‘fusion’ pathways to crc
1334229-04-Results-p02
[ "When", "comparing", "tumours", "with", "a", "missense", "(but", "not", "a", "truncating)", "mutation", "in", "APC", "to", "tumours", "with", "a", "truncating", "mutation", "40%", "67.4–68.3", "relatively", "higher", "frequency", "of", "K-ras", "mutations", "in", "codons", "12", "and", "13", " ", "when", "compared", "to", "colon", "tumours", "(P", "=", "0.05)", "(Table", "3).", "Nine", "per", "cent", "of", "tumours", "showed", "hMLH1", "deficiency,", "as", "determined", "by", "immunohistochemistry", "(Figure", "2).", "Tumours", "lacking", "hMLH1", "expression", "occur", "almost", "exclusively", "in", "the", "proximal", "colon", "(P", "<", "0.001)", "and", "relatively", "more", "frequently", "show", "poor", "differentiation", "or", "are", "undifferentiated", "(P", "<", "0.001)", "when", "compared", "to", "tumours", "with", "hMLH1", "expression", "(Table", "3)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 6, 11, 15, 17, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
When comparing tumours with a missense (but not a truncating) mutation in APC to tumours with a truncating mutation 40% 67.4–68.3 relatively higher frequency of K-ras mutations in codons 12 and 13 when compared to colon tumours (P = 0.05) (Table 3). Nine per cent of tumours showed hMLH1 deficiency, as determined by immunohistochemistry (Figure 2). Tumours lacking hMLH1 expression occur almost exclusively in the proximal colon (P < 0.001) and relatively more frequently show poor differentiation or are undifferentiated (P < 0.001) when compared to tumours with hMLH1 expression (Table 3).
2386495-01-Abstract-p01
[ "Using", "a", "variety", "of", "mutation-detection", "techniques,", "we", "have", "achieved", "a", "100%", "detection", "frequency", "in", "classical", "FAP.", "Probands", "with", "APC", "mutations", "outside", "codon", "1250–1464,", "although", "exhibiting", "a", "less-severe", "phenotype", ",", "are", "at", "high", "risk", "of", "having", "a", "colorectal", "high", "risk", "of", "having", "a", "colorectal", "cancer", " ", "at", "diagnosis", "indicating", "that", "age", "at", "diagnosis", "is", "as", "important", "as", "the", "severity", "of", "the", "disease", "for", "colorectal", " ", "cancer", "morbidity", "Sixty-one", " ", "different", "APC", "mutations", "in", "81", "of", "the", "96", "families", "were", "identified", "and", "27", "of", "those", "are", "novel.", "We", "have", "previously", "shown", "that", "6", "of", "the", "96", "patients", "carried", "biallelic", "MUTYH", "mutations.", "The", "9", "mutation-negative", "cases", "all", "display", "an", "attenuated", "or", "atypical", "phenotype.", "Probands", "with", "a", "genotype", "(codon", "1250–1464)", "predicting", "a", "severe", "phenotype", "had", "a", "median", "age", "at", "diagnosis", "of", "21.8", "(range,", "11–49)", "years", "compared", "with", "34.4", "(range,", "14–57)", "years", "among", "those", "with", "mutations", "outside", "this", "region", "(P", "<", "0.017).", "Dense", "polyposis", "(>", "1000)", "occurred", "in", "75%", "of", "the", "probands", "with", "a", "severe", "phenotype", "compared", "with", "30%", "in", "those", "with", "mutations", "outside", "this", "region.", "The", "morbidity", "in", "colorectal", "cancer", "among", "probands", "was", "25%", "81", "of", "the", "96", "96", " ", "unrelated", "FAP", "patients", "from", "the", "Swedish", "Polyposis", "Registry", "was", "performed.", "In", "addition", "to", "generally", "used", "mutation", "screening", "methods,", "analyses", "of", "splicing-affecting", "mutations", "and", "investigations", "of", "the", "presence", "of", "low-frequency", "mutation", "alleles,", "indicating", "mosaics,", "have", "been", "performed,", "as", "well", "as", "quantitative", "real-time", "polymerase", "chain", "reaction", "to", "detect", "lowered", "expression", "of", "APC." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 7, 8, 0, 0, 0, 0, 0, 0, 0, 0, 3, 17, 18, 18, 18, 18, 18, 18, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 17, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 11, 12, 12, 12, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Using a variety of mutation-detection techniques, we have achieved a 100% detection frequency in classical FAP. Probands with APC mutations outside codon 1250–1464, although exhibiting a less-severe phenotype , are at high risk of having a colorectal high risk of having a colorectal cancer at diagnosis indicating that age at diagnosis is as important as the severity of the disease for colorectal cancer morbidity Sixty-one different APC mutations in 81 of the 96 families were identified and 27 of those are novel. We have previously shown that 6 of the 96 patients carried biallelic MUTYH mutations. The 9 mutation-negative cases all display an attenuated or atypical phenotype. Probands with a genotype (codon 1250–1464) predicting a severe phenotype had a median age at diagnosis of 21.8 (range, 11–49) years compared with 34.4 (range, 14–57) years among those with mutations outside this region (P < 0.017). Dense polyposis (> 1000) occurred in 75% of the probands with a severe phenotype compared with 30% in those with mutations outside this region. The morbidity in colorectal cancer among probands was 25% 81 of the 96 96 unrelated FAP patients from the Swedish Polyposis Registry was performed. In addition to generally used mutation screening methods, analyses of splicing-affecting mutations and investigations of the presence of low-frequency mutation alleles, indicating mosaics, have been performed, as well as quantitative real-time polymerase chain reaction to detect lowered expression of APC.
1266026-05-Discussion-p01
[ "In", "this", "study", "numbers", "of", "mutations", "were", "estimated", "for", "well-defined", "subgroups", "of", "colorectal", "cancers", "because", "biological", "heterogeneity", "may", "confound", "this", "type", "of", "quantitative", "analysis.", "Such", "estimates", "should", "be", "considered", "rough", "guides", "rather", "than", "absolute", "values", "because", "our", "model", "does", "not", "account", "for", "all", "factors.", "Cancers", "were", "classified", "as", "MSI+", "or", "MSI-,", "and", "MSI+", "cancers", "were", "further", "sub-classified", "as", "either", "hereditary", "(HNPCC)", "or", "sporadic.", "As", "expected", "because", "one", "MMR", "mutation", "is", "inherited,", "estimated", "numbers", "of", "critical", "mutations", "were", "less", "for", "MSI+", "HNPCC", "cancers", "compared", "to", "sporadic", "MSI+", "cancers.", "However,", "sporadic", "MSI+", "cancers", "required", "more", "than", "one", "additional", "somatic", "mutation", "sporadic", "cancers", "HNPCC", "cancers", "MSI+", "five", "to", "seven", " ", "oncogenic", "mutations", "[3-6]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 6, 17, 9, 1, 2, 19, 11, 12, 12, 0, 0, 0, 0 ]
In this study numbers of mutations were estimated for well-defined subgroups of colorectal cancers because biological heterogeneity may confound this type of quantitative analysis. Such estimates should be considered rough guides rather than absolute values because our model does not account for all factors. Cancers were classified as MSI+ or MSI-, and MSI+ cancers were further sub-classified as either hereditary (HNPCC) or sporadic. As expected because one MMR mutation is inherited, estimated numbers of critical mutations were less for MSI+ HNPCC cancers compared to sporadic MSI+ cancers. However, sporadic MSI+ cancers required more than one additional somatic mutation sporadic cancers HNPCC cancers MSI+ five to seven oncogenic mutations [3-6].
2386495-01-Abstract-p01
[ "Methods" ]
[ 0 ]
Methods
2386495-04-Results-p01
[ "Mutation", "spectrum", "of", "the", "APC", "colorectal", " ", "polyp", "number", "shows", "that,", "in", "spite", "of", "higher", "age", "at", "diagnosis,", "dense", "polyposis", "(>", "1000)", "only", "occurred", "in", "30%", "of", "the", "probands", "compared", "with", "75%", "in", "those", "with", "mutations", "between", "codon", "1250", "and", "1464.", "In", "the", "former", "group", "29%", "(7", "out", "of", "24)", "had", "CRC", "at", "diagnosis", "compared", "with", "25%", "(2", "out", "of", "8)", "in", "the", "latter", "group.", "The", "mean", "age", "at", "CRC", "was", "46.6", "(range", "28–57)", "and", "37.5", "(range", "26–49)", "years,", "respectively.", "The", "total", "morbidity", "in", "CRC", "among", "probands", "was", "34%", "(11", "out", "of", "32).", "Of", "all", "probands", "diagnosed", "after", "1996,", "four", "out", "of", "nine", " ", "(44%)", "had", "cancer", "at", "diagnosis.", "The", "median", "age", "in", "this", "group", "was", "47.5", "(range", "45–51)", "years", "and", "none", "had,", "despite", "high", "age", "at", "diagnosis", "of", "CRC,", "dense", "colorectal", "polyposis", "at", "diagnosis", "indicating", "a", "less-severe", "phenotype.", "A", "compilation", "of", "clinical", "status", "of", "all", "patients", "analyzed", "in", "this", "study", "is", "shown", "in", "Additional", "file", "1." ]
[ 0, 0, 0, 0, 21, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 12, 12, 12, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Mutation spectrum of the APC colorectal polyp number shows that, in spite of higher age at diagnosis, dense polyposis (> 1000) only occurred in 30% of the probands compared with 75% in those with mutations between codon 1250 and 1464. In the former group 29% (7 out of 24) had CRC at diagnosis compared with 25% (2 out of 8) in the latter group. The mean age at CRC was 46.6 (range 28–57) and 37.5 (range 26–49) years, respectively. The total morbidity in CRC among probands was 34% (11 out of 32). Of all probands diagnosed after 1996, four out of nine (44%) had cancer at diagnosis. The median age in this group was 47.5 (range 45–51) years and none had, despite high age at diagnosis of CRC, dense colorectal polyposis at diagnosis indicating a less-severe phenotype. A compilation of clinical status of all patients analyzed in this study is shown in Additional file 1.
3034663-04-Results-p01
[ "Pedigree", "for", "Family", "#2", "(CRC:", "Colorectal", "cancer", "CRC", " ", "populations", "did", "not", "deviate", "significantly", "from", "that", "expected", "for", "a", "population", "in", "Hardy-Weinberg", "equilibrium", "(Table", "1)." ]
[ 0, 0, 0, 0, 0, 1, 2, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Pedigree for Family #2 (CRC: Colorectal cancer CRC populations did not deviate significantly from that expected for a population in Hardy-Weinberg equilibrium (Table 1).
1619718-04-Results-p01
[ "Mutation", "frequencies", "for", "both", "KRAS", "(P", "<", "0.0001)", "and", "BRAF", "(P", "<", "0.0001)", "are", "distributed", "differently", "across", "the", "seven", "classes", "of", "polyp", "(see", "Results", "for", "individual", "comparisons).", "Distribution", "of", "MGMT", "loss", "differs", "across", "the", "seven", "classes", "of", "polyp", "(P", "<", "0.001)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Mutation frequencies for both KRAS (P < 0.0001) and BRAF (P < 0.0001) are distributed differently across the seven classes of polyp (see Results for individual comparisons). Distribution of MGMT loss differs across the seven classes of polyp (P < 0.001).
1557864-03-Methods-p01
[ "All", "cell", "lines", "were", "cultured", "in", "medium", "supplemented", "with", "100", "U/ml", "penicillin,", "100", "μg/ml", "streptomycin", "and", "50", "μg/ml", "gentamycin", "at", "37°C", "in", "humidified", "air", "with", "5%", "CO2", "(except", "for", "SW48", "which", "was", "cultured", "with", "10%", "CO2).", "The", "human", "ovarian", "cancer", "cell", "lines", "SKOV6,", "HOC7,", "SKOV3,", "2774,", "KB3.1", "and", "CAOV3", "were", "cultured", "in", "DMEM/HAMF12", "medium", "with", "10%", "fetal", "calf", "serum,", "A2780", "in", "RPMI", "1640", "medium", "with", "10%", "fetal", "calf", "serum", "and", "OVCAR3", "in", "RPMI", "1640", "with", "20%", "fetal", "calf", "serum", "and", "0.01", "mg/ml", "insulin.", "The", "human", "colon", "cancer", "cell", "lines", "SW480", "and", "SW48,", "included", "as", "controls,", "were", "cultured", "in", "RPMI", "1640", "with", "5%", "fetal", "calf", "serum", "and", "DMEM/HAMF12", "with", "10%", "fetal", "calf", "serum", "respectively.", "The", "ovarian", "cancer", "cell", "line", "A2780", "has", "been", "cultured", "separately", "in", "two", "different", "research", "laboratories", "at", "our", "department.", "The", "isolated", "DNA", "and", "RNA", "from", "each", "culture", "were", "used", "for", "further", "analysis." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
All cell lines were cultured in medium supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin and 50 μg/ml gentamycin at 37°C in humidified air with 5% CO2 (except for SW48 which was cultured with 10% CO2). The human ovarian cancer cell lines SKOV6, HOC7, SKOV3, 2774, KB3.1 and CAOV3 were cultured in DMEM/HAMF12 medium with 10% fetal calf serum, A2780 in RPMI 1640 medium with 10% fetal calf serum and OVCAR3 in RPMI 1640 with 20% fetal calf serum and 0.01 mg/ml insulin. The human colon cancer cell lines SW480 and SW48, included as controls, were cultured in RPMI 1640 with 5% fetal calf serum and DMEM/HAMF12 with 10% fetal calf serum respectively. The ovarian cancer cell line A2780 has been cultured separately in two different research laboratories at our department. The isolated DNA and RNA from each culture were used for further analysis.
2386495-05-Discussion-p04
[ "Owing", "to", "the", "fact", "that", "RNA-based", "PTT", "was", "used", "at", "the", "initial", "stage", "of", "the", "mutational", "screening,", "detection", "of", "the", "disease-causing", "splice-site", "mutations", "was", "straightforward.", "Sequencing", "of", "genomic", "DNA", "was", "then", "used", "to", "pinpoint", "the", "genetic", "alteration", "causing", "the", "aberrant", "mRNA", "sequence", "that", "was", "visualized", "in", "the", "PTT", "experiments.", "The", "use", "of", "both", "DNA-", "and", "mRNA-based", "methods", "is", "a", "prerequisite", "for", "high-quality", "investigation", "of", "splice-site", "mutations." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Owing to the fact that RNA-based PTT was used at the initial stage of the mutational screening, detection of the disease-causing splice-site mutations was straightforward. Sequencing of genomic DNA was then used to pinpoint the genetic alteration causing the aberrant mRNA sequence that was visualized in the PTT experiments. The use of both DNA- and mRNA-based methods is a prerequisite for high-quality investigation of splice-site mutations.
1334229-02-Background-p01
[ "Genetic", "instability", "is", "seen", "in", "most", "types", "of", "cancer", "[10].", "Two", "distinct", "types", "of", "genetic", "instability", "appear", "to", "occur", "in", "colorectal", "cancer", "[11]:", "chromosomal", "and", "microsatellite", "instability.", "Chromosomal", "instability", "cancer", "TP53", ")", "and", "oncogenes", "(e.g.", "CTNNB1,", "K-ras)", "[3,4].", "Important", "molecular", "pathways", "that", "upon", "activation", "affect", "the", "early", "and", "intermediate", "stages", "of", "colorectal", "carcinogenesis", "are", "the", "Wnt", "and", "Ras", "signalling", "pathways,", "whereas", "TP53", "inactivation", "is", "considered", "a", "late", "event." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 19, 20, 1, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Genetic instability is seen in most types of cancer [10]. Two distinct types of genetic instability appear to occur in colorectal cancer [11]: chromosomal and microsatellite instability. Chromosomal instability cancer TP53 ) and oncogenes (e.g. CTNNB1, K-ras) [3,4]. Important molecular pathways that upon activation affect the early and intermediate stages of colorectal carcinogenesis are the Wnt and Ras signalling pathways, whereas TP53 inactivation is considered a late event.
1619718-04-Results-p02
[ "With", "respect", "to", "the", "25", "serrated", "polyps", "with", "dysplasia,", "only", "five", "serrated", " ", "polyps", "in", "which", "the", "epithelial", "dysplasia", "appeared", "adenomatous", "(Figure", "1C,D).", "BRAF", "mutation", "occurred", "in", "10/16", "Group", "A", "polyps", "but", "only", "1/9", "Group", "B", "polyps", "(P", "<", "0.03).", "KRAS", "mutation", "occurred", "in", "only", "3/16", "Group", "A", "polyps", "but", "in", "5/9", "Group", "B", "polyps", "(P", "=", "0.06).", "In", "each", "of", "the", "five", "Group", "B", "polyps", "with", "KRAS", "mutation,", "the", "adenomatous", "component", "showed", "both", "villous", "change", "and", "serration." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 17, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
With respect to the 25 serrated polyps with dysplasia, only five serrated polyps in which the epithelial dysplasia appeared adenomatous (Figure 1C,D). BRAF mutation occurred in 10/16 Group A polyps but only 1/9 Group B polyps (P < 0.03). KRAS mutation occurred in only 3/16 Group A polyps but in 5/9 Group B polyps (P = 0.06). In each of the five Group B polyps with KRAS mutation, the adenomatous component showed both villous change and serration.
1360090-03-Results-p01
[ "We", "next", "examined", "whether", "the", "characteristic", "features", "of", "tumors", "with", "BRAF", "mutation", "were", "still", "apparent", "following", "stratification", "into", "MSI", "and", "CIMP", "phenotypes.", "Although", "the", "statistical", "power", "of", "this", "subgroup", "analysis", "was", "limited,", "the", "morphological", "features", "of", "infiltrating", "lymphocytes,", "poor", "histological", "grade", "and", "mucinous", "appearance", "were", "clearly", "associated", "with", "BRAF", "mutation", "regardless", "of", "tumor", "MSI", "status", "(Table", "3).", "Similarly,", "these", "features", "were", "each", "more", "common", "in", "tumors", "with", "BRAF", "mutation", "in", "both", "the", "CIMP-", "and", "CIMP+", "subgroups", "(Table", "4).", "Similar", "to", "previous", "observations", "in", "a", "separate", "CRC", "cohort", "[20],", "the", "frequency", "of", "KRAS", " ", "mutation", "was", "lower", "in", "MSI+", "compared", "to", "MSI-", "tumors", "(P", "=", "0.034;", "Table", "3),", "while", "the", "frequency", "of", "TP53", "colorectal", "cancer", ".", "WT,", "wild-type;", "M,", "mutation.", "(B)", "DNA", "sequencing", "gel", "resultconfirms", "the", "presence", "of", "a", "1799T", "to", "A", "mutation", "giving", "rise", "to", "the", "V600E", "mutation." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 1, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
We next examined whether the characteristic features of tumors with BRAF mutation were still apparent following stratification into MSI and CIMP phenotypes. Although the statistical power of this subgroup analysis was limited, the morphological features of infiltrating lymphocytes, poor histological grade and mucinous appearance were clearly associated with BRAF mutation regardless of tumor MSI status (Table 3). Similarly, these features were each more common in tumors with BRAF mutation in both the CIMP- and CIMP+ subgroups (Table 4). Similar to previous observations in a separate CRC cohort [20], the frequency of KRAS mutation was lower in MSI+ compared to MSI- tumors (P = 0.034; Table 3), while the frequency of TP53 colorectal cancer . WT, wild-type; M, mutation. (B) DNA sequencing gel resultconfirms the presence of a 1799T to A mutation giving rise to the V600E mutation.
2386495-03-Methods-p01
[ "Patients", "without", "any", "detected", "mutation", "in", "APC", "or", "MUTYH" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Patients without any detected mutation in APC or MUTYH
1334229-03-Methods-p03
[ "Analysis", "of", "the", "BAT-26", "mononucleotide", "repeat", "was", "performed", "in", "a", "random", "sample", "of", "tumour", "specimens", "from", "114", "patients,", "and", "a", "series", "of", "48", "of", "58", "tumours", "that", "lacked", "hMLH1", "expression,", "to", "assess", "the", "concordance", "between", "the", "microsatellite", "instability", "marker", "BAT-26", "and", "hMLH1", "expression.", "The", "primer", "sequences", "and", "PCR", "conditions", "for", "the", "BAT-26", "mononucleotide", "repeat", "were", "used", "as", "described", "previously", "[31]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Analysis of the BAT-26 mononucleotide repeat was performed in a random sample of tumour specimens from 114 patients, and a series of 48 of 58 tumours that lacked hMLH1 expression, to assess the concordance between the microsatellite instability marker BAT-26 and hMLH1 expression. The primer sequences and PCR conditions for the BAT-26 mononucleotide repeat were used as described previously [31].
2275286-06-Conclusion-p01
[ "Our", "results", "imply", "that", "HNPCC", "in", "the", "Chinese", "population", "may", "have", "distinct", "clinicopathological", "characteristics", "and", "underlying", "MMR", "germline", "mutations,", "as", "compared", "to", "patients", "from", "Western", "countries.", "Application", "of", "NCI", "recommendations", "on", "the", "Chinese", "population", " ", "may", "have", "distinct", "clinicopathological", "characteristics", "and", "underlying", "MMR", "germline", "mutations,", "as", "compared", "to", "patients", "from", "Western", "countries.", "Application", "of", "NCI", "recommendations", "on", "the", "Chinese", "population", "may", "not", "enable", "the", "screening", "of", "all", "HNPCC", "families", "Chinese", " ", "population", "may", "have", "distinct", "clinicopathological", "characteristics", "and", "underlying", "MMR", "germline", "mutations,", "as", "compared", "to", "patients", "from", "Western", " ", "countries.", "Application", "of", "NCI", "recommendations", "on", "the", "Chinese", "population", "MMR", " ", "germline", "mutations", "HNPCC", " ", "in", "the", "Chinese", "population", "may", "have", "distinct", "clinicopathological", "characteristics", "and", "underlying", "MMR", "germline", "mutations,", "as", "compared", "to", "patients", " ", "from", "Western", "countries.", "Application", "of", "NCI", "recommendations", "on", "the", "Chinese", "population", "may", "not", "enable", "the", "screening", "of", "all", "HNPCC", " ", "families.", "Further", "studies", "are", "necessary", "to", "echo", "or", "refute", "our", "results", "so", "as", "to", "make", "the", "NCI", "recommendation", "more", "universally", "applicable." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 25, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 25, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 25, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 21, 0, 5, 6, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Our results imply that HNPCC in the Chinese population may have distinct clinicopathological characteristics and underlying MMR germline mutations, as compared to patients from Western countries. Application of NCI recommendations on the Chinese population may have distinct clinicopathological characteristics and underlying MMR germline mutations, as compared to patients from Western countries. Application of NCI recommendations on the Chinese population may not enable the screening of all HNPCC families Chinese population may have distinct clinicopathological characteristics and underlying MMR germline mutations, as compared to patients from Western countries. Application of NCI recommendations on the Chinese population MMR germline mutations HNPCC in the Chinese population may have distinct clinicopathological characteristics and underlying MMR germline mutations, as compared to patients from Western countries. Application of NCI recommendations on the Chinese population may not enable the screening of all HNPCC families. Further studies are necessary to echo or refute our results so as to make the NCI recommendation more universally applicable.
3034663-04-Results-p01
[ "In", "the", "second", "LS", "family,", "the", "index", "subject,", "one", "sister", "and", "one", "brother", "with", "CRC", "(II-5;", "II-6;", "II-7,", "respectively)", "had", "a", "deleterious", "variant", "in", "MSH6", "(c.3013C>T;", "p.Arg1005X)", "but", "did", "not", "have", "the", "p.Lys618Ala", "variant.", "This", "variant", "was", "present", "in", "only", "three", "of", "four", "unaffected", "nephews", "(III-2;", "III-3;", "III-4)", "and", "was", "inherited", "from", "the", "parental", "branch,", "in", "which", "there", "was", "no", "familial", "history", "of", "cancer.", "Individuals", "III-3", "and", "III-4", "inherited", "also", "the", "deleterious", "variant.", "No", "genetic", "testing", "was", "available", "from", "the", "father", "or", "paternal", "relatives", "(Family", "#2,", "Figure", "3)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
In the second LS family, the index subject, one sister and one brother with CRC (II-5; II-6; II-7, respectively) had a deleterious variant in MSH6 (c.3013C>T; p.Arg1005X) but did not have the p.Lys618Ala variant. This variant was present in only three of four unaffected nephews (III-2; III-3; III-4) and was inherited from the parental branch, in which there was no familial history of cancer. Individuals III-3 and III-4 inherited also the deleterious variant. No genetic testing was available from the father or paternal relatives (Family #2, Figure 3).
1334229-03-Methods-p03
[ "Formalin-fixed,", "paraffin-embedded", "tissue", "sections", "cut", "at", "4", "μm,", "which", "included", "tumour", "tissue", "with", "normal", "adjacent", "mucosa,", "were", "used", "for", "immunohistochemistry.", "Endogenous", "peroxidase", "activity", "was", "blocked", "by", "3%", "H2O2.", "Slides", "were", "submitted", "to", "microwave", "antigen", "retrieval", "in", "1", "mM", "EDTA", "buffer", "(pH", "8.0)", "and", "incubated", "with", "10%", "normal", "horse", "serum", "for", "ten", "min", "at", "room", "temperature.", "Then,", "sections", "were", "incubated", "overnight", "at", "4°C", "with", "mouse", "monoclonal", "antibodies", "against", "hMLH1", "protein", "(clone", "G168-15,", "PharMingen,", "San", "Diego,", "CA)", "at", "a", "1:100", "dilution.", "Antibody", "binding", "was", "detected", "by", "incubating", "the", "sections", "at", "room", "temperature", "with", "the", "peroxidase-labelled", "DAKO", "Envision", "System", "(DAKO,", "Carpinteris,", "CA),", "using", "DAB", "as", "a", "chromogen.", "Sections", "were", "counterstained", "with", "diluted", "haematoxylin." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Formalin-fixed, paraffin-embedded tissue sections cut at 4 μm, which included tumour tissue with normal adjacent mucosa, were used for immunohistochemistry. Endogenous peroxidase activity was blocked by 3% H2O2. Slides were submitted to microwave antigen retrieval in 1 mM EDTA buffer (pH 8.0) and incubated with 10% normal horse serum for ten min at room temperature. Then, sections were incubated overnight at 4°C with mouse monoclonal antibodies against hMLH1 protein (clone G168-15, PharMingen, San Diego, CA) at a 1:100 dilution. Antibody binding was detected by incubating the sections at room temperature with the peroxidase-labelled DAKO Envision System (DAKO, Carpinteris, CA), using DAB as a chromogen. Sections were counterstained with diluted haematoxylin.
3034663-03-Methods-p01
[ "Three", "characterized", "LS", "families", "that", "fulfilled", "the", "Amsterdam", "II", "Criteria", "and", "that", "consisted", "of", "members", "with", "the", "p.Lys618Ala", "variant", "were", "included", "to", "assess", "co-occurrence", "and", "co-segregation.", "Two", "families", "attended", "the", "Genetic", "Counselling", "in", "Cancer", "Units", "of", "the", "Elche", "and", "La", "Fe", "Hospitals", "and", "one", "family", "was", "a", "member", "of", "the", "EPICOLON", "cohort", "[7]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Three characterized LS families that fulfilled the Amsterdam II Criteria and that consisted of members with the p.Lys618Ala variant were included to assess co-occurrence and co-segregation. Two families attended the Genetic Counselling in Cancer Units of the Elche and La Fe Hospitals and one family was a member of the EPICOLON cohort [7].
1266026-03-Methods-p01
[ "Numbers", "of", "oncogenic", "alterations", "(genetic", "mutations", "or", "epigenetic", "alterations)", "required", "for", "transformation", "were", "estimated", "from", "ages", "at", "cancer", "using", "a", "Bayesian", "approach", "as", "previously", "described", "[11].", "This", "method", "requires", "the", "use", "of", "a", "life", "table", "from", "census", "data:", "for", "the", "Finnish", "data", "set", "we", "used", "a", "Finnish", "life", "table", "from", "the", "World", "Health", "Organization", "website", ",", "for", "the", "SEER", "dataset", "we", "used", "a", "United", "States", "germline", "mutations", "Finnish", " ", "MLH1", "germline", "mutations)", "or", "by", "direct", "genomic", "sequencing", "of", "coding", "exons", "[9].", "The", "data", "can", "be", "downloaded", "from", "the", "following", "website:", ".", "Approval", "for", "this", "research", "was", "obtained", "from", "the", "appropriate", "ethics", "committees,", "which", "are", "in", "compliance", "with", "the", "Helsinki", "Declaration." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 25, 26, 5, 6, 25, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Numbers of oncogenic alterations (genetic mutations or epigenetic alterations) required for transformation were estimated from ages at cancer using a Bayesian approach as previously described [11]. This method requires the use of a life table from census data: for the Finnish data set we used a Finnish life table from the World Health Organization website , for the SEER dataset we used a United States germline mutations Finnish MLH1 germline mutations) or by direct genomic sequencing of coding exons [9]. The data can be downloaded from the following website: . Approval for this research was obtained from the appropriate ethics committees, which are in compliance with the Helsinki Declaration.
3034663-03-Methods-p01
[ "Three", "characterized", "LS", "families", "that", "fulfilled", "the", "Amsterdam", "II", "Criteria", "and", "that", "consisted", "of", "members", "with", "the", "p.Lys618Ala", "variant", "were", "included", "to", "assess", "co-occurrence", "and", "co-segregation.", "Two", "families", "attended", "the", "Genetic", "Counselling", "in", "Cancer", "Units", "of", "the", "Elche", "and", "La", "Fe", "Hospitals", "and", "one", "family", "was", "a", "member", "of", "the", "EPICOLON", "cohort", "[7]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Three characterized LS families that fulfilled the Amsterdam II Criteria and that consisted of members with the p.Lys618Ala variant were included to assess co-occurrence and co-segregation. Two families attended the Genetic Counselling in Cancer Units of the Elche and La Fe Hospitals and one family was a member of the EPICOLON cohort [7].